The ProALL lab tests predict relapse risk of acute lymphoblastic leukemia patients. The test measures the levels of three microRNA molecules. ProALL BM test is a prognostic assay measuring microRNA in bone marrow taken for the diagnostic procedures. ProALL Blood test is monitoring assay measuring the microRNA in blood samples taking during and after treatment. Results from ProALL BM are used for deciding on intense or standard treatment for the leukemia patient. Results from the ProALL Blood test are used for detecting molecular relapse before clinical relapse, so the window of opportunity for successful treatment is not missed. ProALL will save and improve the quality of life of young cancer patients, taking a 20-year-old art to the state- of-the-art of the 21st century.
Curewize is performing groundbreaking research on the development of a companion diagnostic test for several cancers. Stay tuned for more information on our exciting new products.
Curewize has created an accurate industrial platform technology for producing preditive and diagnostic assays based on microRNA. Curewize is discussing with several potential partners the industrilization of groundbreaking microRNA test using our platform technolgy. Curewize's infrastructure and know-how will allow the fast and efficient market entry of a large portfolio of products.